Olema Oncology (OLMA) closed at $7.02 on November 20, 2026, down 1.8% from the previous close, on volume of 1,213,105 shares (30-day average 1,387,842).
Data as of November 20, 2026.
20-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 11, 2026 | Call Spread | 21-Jan-288 : 10 C | 400 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 20, 2026. See the largest for 5, 30, 60 and 90 days
Globe Newswire (Wed, 18-Nov 2:30 AM ET)
Olema Oncology to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 16-Nov 4:30 PM ET)
Olema Oncology Announces Corporate Name Change
Globe Newswire (Thu, 12-Nov 9:00 AM ET)
Olema Oncology Reports Third Quarter 2026 Financial and Operating Results
Globe Newswire (Tue, 10-Nov 7:00 AM ET)
Globe Newswire (Wed, 4-Nov 4:01 PM ET)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 3-Nov 4:30 PM ET)
Market Chameleon (Fri, 22-May 3:50 AM ET)
Olema Oncology to Highlight Its Advancing Pipeline at Three Major Investor Conferences
Market Chameleon (Wed, 20-May 4:43 AM ET)
Market Chameleon (Fri, 21-Nov 3:34 AM ET)
Olema Oncology Inc is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. The company's lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), is currently in two Phase 3 clinical trials. In addition, Olema is focused in developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor.
Olema Oncology trades on the NASDAQ stock market under the symbol OLMA.
As of November 20, 2026, OLMA stock price declined to $7.02 with 1,213,105 million shares trading.
OLMA has a beta of 0.83, meaning it tends to be less sensitive to market movements. OLMA has a correlation of 0.01 to the broad based SPY ETF.
OLMA has a market cap of $615.00 million. This is considered a Small Cap stock.
Last quarter Olema Oncology reported $0 in Revenue and -$.73 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.10.
In the last 3 years, OLMA traded as high as $36.26 and as low as $2.86.
The top ETF exchange traded funds that OLMA belongs to (by Net Assets): XBI, IWM, VTI, VXF, IWN.
OLMA has underperformed the market in the last year with a return of -68.1%, while the SPY ETF gained +6.9%. In the last 3 month period, OLMA fell short of the market, returning -35.6%, while SPY returned -9.3%. However, in the most recent 2 weeks OLMA has outperformed the stock market by returning -4.2%, while SPY returned -6.2%.
OLMA support price is $6.76 and resistance is $7.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OLMA shares will trade within this expected range on the day.